Illumina (NASDAQ:ILMN) Posts Quarterly Earnings Results

Illumina (NASDAQ:ILMN) announced its quarterly earnings results on Thursday. The life sciences company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.26 by $0.09, FiscalAI reports. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.95 earnings per share. Illumina updated its FY 2026 guidance to 5.050-5.200 EPS.

Here are the key takeaways from Illumina’s conference call:

• Illumina beat Q4 expectations with $1.16B in revenue, delivered 20% clinical consumables growth ex?China in Q4, expanded non?GAAP operating margin and returned roughly $740M to shareholders via buybacks.
• High?throughput momentum: the company placed >100 NovaSeq X systems in Q4 (active install base ~890), total sequencing output grew >30% YoY, and conversion to NovaSeq X is largely complete for research customers, driving consumables pull?through.
• Strategic expansion into multi?omics and data/software: closed the SomaLogic acquisition (upfront $350M), launched BioInsight and the Billion Cell Atlas, and announced initial pharma collaborations (AstraZeneca, Merck, Eli Lilly).
• 2026 outlook is modestly positive but mixed: guidance of $4.5–$4.6B (2%–4% organic ex?China) and EPS $5.05–$5.20 (includes $0.18 SomaLogic dilution) while China export restrictions, tariff headwinds (~205 bps impact) and expected mid?to?high single?digit research declines pose risks.

Illumina Trading Down 0.4%

NASDAQ ILMN opened at $133.61 on Friday. Illumina has a 1 year low of $68.70 and a 1 year high of $155.53. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The company has a market capitalization of $20.42 billion, a PE ratio of 29.96, a P/E/G ratio of 2.23 and a beta of 1.45. The company has a fifty day moving average of $138.67 and a 200 day moving average of $115.99.

Insider Buying and Selling at Illumina

In other news, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the transaction, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. The trade was a 1.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Illumina

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Quarry LP acquired a new stake in shares of Illumina in the third quarter valued at about $32,000. Advisory Services Network LLC purchased a new position in Illumina in the 3rd quarter valued at about $102,000. Headlands Technologies LLC acquired a new stake in Illumina in the 2nd quarter worth about $165,000. Glenmede Investment Management LP purchased a new stake in Illumina during the 3rd quarter worth approximately $220,000. Finally, Voleon Capital Management LP acquired a new position in shares of Illumina during the third quarter valued at approximately $220,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

ILMN has been the topic of several research reports. TD Cowen reissued a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Guggenheim lifted their price target on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a report on Monday, January 26th. Evercore ISI reaffirmed an “outperform” rating and issued a $155.00 price objective on shares of Illumina in a research report on Monday, January 5th. Canaccord Genuity Group increased their target price on shares of Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a research report on Monday, January 26th. Finally, Robert W. Baird set a $109.00 price target on Illumina in a research report on Friday, October 31st. Six analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Hold” and an average target price of $127.18.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q4 earnings beat — Illumina reported $1.35 GAAP/non?GAAP EPS (beat consensus) and $1.16B in revenue (above estimates), showing 5% YoY revenue growth for the quarter. This confirms near?term operating leverage and profitability. Zacks: Tops Q4 Estimates
• Positive Sentiment: FY2026 revenue guide lifted — Illumina gave 2026 revenue guidance of $4.5B–$4.6B (above Street revenue consensus), signaling expected mid-single-digit growth and underlying demand momentum. That revenue guide is a key upside catalyst for FY26. Press Release / Guidance
• Positive Sentiment: Operational tailwinds — Management highlighted clinical consumables growth, expansion into multiomics and margin momentum (non?GAAP op margin guidance ~23.3–23.5%), supporting durable revenue mix improvement and higher-margin recurring revenue. Yahoo Deep Dive
• Neutral Sentiment: SomaLogic acquisition and dilution — Guidance includes ~$0.18 EPS dilution and ~100bps margin headwind from the recently closed SomaLogic deal; strategic for multiomics but a modest near?term drag. PR Newswire: Financial Results
• Neutral Sentiment: Full call and disclosures available — The earnings call transcript, slide deck and SEC/press materials are posted for deeper review of segment trends and backlog — useful for modeling revenue cadence and margin drivers. Seeking Alpha Transcript
• Negative Sentiment: FY2025 revenue flat — Full-year 2025 revenue was essentially flat vs. 2024, a disappointment to some investors who had hoped for stronger recovery; this disappointment is the main reason shares are down despite the quarterly beat. Investing.com: Shares Tumble

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.